Actively Recruiting
Phase 1b Trial of QX1206 Drug for Adults With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
Led by 1Globe Health Institute · Updated on 2025-01-13
52
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating QX1206 in an open-label phase 1b trial involving adults with Type 2 Diabetes Mellitus T2DM and Non-Alcoholic Fatty Liver Disease NAFLD. The study aims to determine the recommended dose for future studies and examine the preliminary effects of QX1206 on blood sugar control and other metabolic factors. Participants will take QX1206 orally before bedtime. The trial will last up to 12 weeks, during which laboratory tests and measurements will be taken before the first dose and throughout the study to monitor effects and safety. The study focuses on finding the best dose and assessing changes in blood sugar and insulin resistance. During the study, participants will undergo regular assessments including blood tests for hemoglobin A1c, fasting glucose, insulin levels, and insulin resistance. Researchers will track the recommended phase 2 dose from day 1 through week 12. Patients must comply with study procedures and attend all visits. The total participation period is up to 12 weeks.
CONDITIONS
Brief Title
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
Research Team
1
1Globe Health Institute
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
